Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use

Zoltán Papp, Piergiuseppe Agostoni, Julian Alvarez, Dominique Bettex, Stefan Bouchez, Dulce Brito, Vladimir Černý, Josep Comin-Colet, Marisa G. Crespo-Leiro, Juan F. Delgado, István Édes, Alexander A. Eremenko, Dimitrios Farmakis, Francesco Fedele, Cândida Fonseca, Sonja Fruhwald, Massimo Girardis, Fabio Guarracino, Veli Pekka Harjola, Matthias HeringlakeAntoine Herpain, Leo M.A. Heunks, Tryggve Husebye, Višnja Ivancan, Kristjan Karason, Sundeep Kaul, Matti Kivikko, Janek Kubica, Josep Masip, Simon Matskeplishvili, Alexandre Mebazaa, Markku S. Nieminen, Fabrizio Oliva, Julius G. Papp, John Parissis, Alexander Parkhomenko, Pentti Põder, Gerhard Pölzl, Alexander Reinecke, Sven Erik Ricksten, Hynek Riha, Alain Rudiger, Toni Sarapohja, Robert H.G. Schwinger, Wolfgang Toller, Luigi Tritapepe, Carsten Tschöpe, Gerhard Wikström, Dirk Von Lewinski, Bojan Vrtovec, Piero Pollesello

Research output: Contribution to journalReview articlepeer-review

51 Citations (Scopus)
Original languageEnglish
Pages (from-to)4-22
Number of pages19
JournalJournal of Cardiovascular Pharmacology
Volume76
Issue number1
DOIs
Publication statusPublished - 2020
Externally publishedYes

ASJC Scopus Subject Areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Keywords

  • acute heart failure
  • advanced heart failure
  • hemodynamics
  • inodilator
  • inotrope
  • neurohormone
  • regulatory clinical trial

Fingerprint

Dive into the research topics of 'Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use'. Together they form a unique fingerprint.

Cite this